PGR positive

P1, N=28, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Aug 2026

P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027

Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.

Although ACCB generally has a good prognosis, the treatment of this rare type of breast cancer remains challenging to ensure favorable outcomes with minimal sequelae. Initial staging and long-term follow-up using appropriate imaging modalities are essential for selecting tailored treatment strategies and detecting early relapses.

Unlike the canonical activation of PAR1 by thrombin, which enhances cell proliferation via mechanistic target of rapamycin (mTOR) signaling, HAP-induced noncanonical activation downregulates mTOR activation and triggers autophagy in both estrogen receptor positive/ progesterone receptor positive/ HER2 negative (ER+/PR+/HER2-) and triple negative (ER-/PR-/HER2-) breast cancer cells...Importantly, the lack of PAR1 expression in normal, healthy breast epithelial cells facilitates the peptide to selectively target breast cancer cells with relatively high PAR1 expression, highlighting its potential as a therapeutic agent against low-grade malignant breast tumor. These findings provide valuable insights into autophagy activation by a synthetic peptide that targets breast cancer cells with high PAR1 expression and for the first time shows peptide mediated targeted therapy of low-grade malignant breast tumor.

P1, N=46, Completed, Ono Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed

P=N/A, N=400, Not yet recruiting, IceCure Medical Ltd.

P3, N=1155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2027 --> Aug 2026 | Trial primary completion date: May 2027 --> Aug 2026

These findings suggest that IGF-1 and IGFBP-3 may have potential as candidate biomarkers for breast cancer risk and progression. Integrating genetic, biochemical, and hormone receptor status provides novel insights into breast cancer biology and may support future research on personalized prevention and treatment strategies, particularly in resource-limited settings such as the Gaza Strip.

P=N/A, N=170, Recruiting, AstraZeneca | N=70 --> 170

Of the 10 patients, 60% experienced adverse events, including one grade 3 increase in gamma-glutamyltransferase. In conclusion, ONA-XR showed early tumor proliferation suppression, particularly in high PgR-expressing tumors, supporting its potential for further clinical evaluation.

P4, N=500, Recruiting, Ottawa Hospital Research Institute | Active, not recruiting --> Recruiting | N=109 --> 500 | Trial completion date: Feb 2029 --> May 2036 | Trial primary completion date: Feb 2029 --> May 2036